Developer docs
API playgroundTry for free, no card

Search company profiles

ModeX Therapeutics

Full company profile

uuid00085vj

Namestring
ModeX Therapeutics
Legal namestring
ModeX Therapeutics
Websiteurl
modextx.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

ModeX Therapeutics is a clinical-stage biopharmaceutical company founded in 2020 and operating as a wholly-owned subsidiary of OPKO Health (NASDAQ: OPK). The company is headquartered at 20 Riverside Road, Weston, Massachusetts and employs 11–50 staff. Its scientific mission is to engineer multispecific antibodies — single molecules that engage multiple biological targets simultaneously — to address complex diseases in oncology, infectious disease, immunology, and metabolic disorders.

ModeX develops its candidates through two proprietary modular platforms: the MSTAR platform, which enables design of multispecific antibodies combining multiple biologics in a single molecule, and a Nanoparticle Vaccine Platform, which presents multiple antigens for infectious disease prevention. The current clinical pipeline comprises five programs: MDX2003 (tetraspecific T-cell engager in Phase I for relapsed/refractory B-cell lymphoma), MDX2301 (tetravalent bispecific COVID-19 antibody in Phase I, BARDA-funded), MDX2004 (trispecific antibody in Phase 1/2a for advanced cancers and immune disorders), an EBV vaccine in collaboration with Merck (Phase I, 200+ subjects enrolled), and a preclinical in-vivo CAR-T program targeting first-in-human trials by end-2026 or early-2027.

ModeX generates no product revenue; its economics flow from licensing and milestone payments under collaboration agreements and federal contract funding. The October 2025 Regeneron license and collaboration agreement delivered a $7M upfront with potential milestones exceeding $200M per selected molecule and an aggregate potential value above $1B. BARDA provides non-dilutive funding for the MDX2301 Phase 1 program. The Merck EBV vaccine partnership provides milestone-linked economics. Co-founders are Elias Zerhouni (Chairman; also OPKO Health President and Vice Chairman) and Gary Nabel (President and CEO; also OPKO Health Chief Innovation Officer). Scientific leadership includes CSO John Mascola (former Director of the NIH Vaccine Research Center, NIAID), COO Ji Zhang (formerly Senior Partner at Flagship Pioneering), and CMOs/CDOs with deep biotech drug-development backgrounds.

Short descriptiontext

ModeX Therapeutics is a clinical-stage biopharmaceutical subsidiary of OPKO Health that develops multispecific antibody therapeutics for oncology, infectious diseases, immunology, and metabolic disorders using proprietary MSTAR and Nanoparticle Vaccine platforms, monetized through licensing and milestone payments.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersWeston, United States
HQ citystring
Weston
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
multispecific antibody therapeutics, bispecific antibody engineering, immuno-oncology biologics, infectious disease antibodies, nanoparticle vaccine development
Industry4 codes
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Therapeutics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Licensing and Milestone Payments (Regeneron Collaboration)
TypeLicensing Royalties
Description

ModeX receives upfront payments and potential milestone payments exceeding $200 million per selected molecule from Regeneron, with overall collaboration value exceeding $1 billion if multiple products advance successfully. Revenue is generated through preclinical, clinical, and commercial milestones.

stocktitan.net
2Federal Contract Funding (BARDA)
TypeLicensing Royalties
Description

ModeX receives federal funding from the U.S. Biomedical Advanced Research and Development Authority (BARDA) for the MDX2301 COVID-19 antibody program, supporting Phase 1 clinical trial costs.

finance.yahoo.com
3Collaboration Revenue (Merck EBV Vaccine)
TypeLicensing Royalties
Description

OPKO's collaboration with Merck involves an Epstein-Barr virus vaccine study that has enrolled over 200 subjects in Phase 1, with milestone payments tied to subgroup analyses and Phase II design decisions.

finance.yahoo.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ModeX Therapeutics is a clinical-stage biopharmaceutical company developing multispecific antibody therapeutics using its proprietary MSTAR Platform and Nanoparticle Vaccine Platform. The company engineers single molecules that combine multiple biologics to simultaneously target distinct biological pathways, addressing cancer, infectious diseases, immunology, and metabolic disorders. Its pipeline includes MDX2003 (tetraspecific T-cell engager for B-cell lymphoma), MDX2301 (tetravalent bispecific antibody for COVID-19 prevention), MDX2004 (trispecific antibody for advanced cancers and immune disorders), an EBV vaccine developed with Merck, and an in-vivo CAR-T program.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over five tetraspecific antibodies are currently in clinical trials with first approval expected by 2032
+2 more records
Product overview1 text field

ModeX Therapeutics is a biopharmaceutical company developing multispecific antibody therapeutics using its proprietary modular platforms. The company operates two core technology platforms: the MSTAR Platform for developing multispecific antibodies and a Nanoparticle Vaccine Platform. The clinical pipeline includes MDX2003 (tetraspecific T-cell engager for B-cell lymphoma), MDX2301 (tetravalent bispecific antibody for COVID-19 prevention), MDX2004 (trispecific antibody for advanced cancers and immune disorders), an EBV vaccine (in collaboration with Merck), and an in-vivo CAR-T program. ModeX is a subsidiary of OPKO Health and has a strategic collaboration with Regeneron worth over $1 billion to develop multispecific antibodies targeting immunology, oncology, and metabolic diseases.

Product and service4 records
1MDX2003
CategoryClinical-stage oncology therapeutic candidate
2MDX2301
CategoryClinical-stage infectious disease antibody
3MDX2004
CategoryClinical-stage immuno-oncology therapeutic candidate
4Epstein-Barr Virus (EBV) Vaccine
CategoryClinical-stage infectious disease vaccine
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-28
Description

OPKO Health's collaboration with Merck involves an Epstein-Barr virus (EBV) vaccine study that has enrolled over 200 subjects in a Phase 1 study, with subgroup analyses underway. Data is expected to inform Phase II design by year-end.

2U.S. Biomedical Advanced Research and Development Authority (BARDA)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-09
Description

BARDA is funding the Phase 1 clinical trial of MDX2301, a tetravalent bispecific antibody for COVID-19 prevention, under a federal contract from the U.S. Department of Health and Human Services. The funding supports evaluation of safety, tolerability, pharmacokinetics, and neutralizing activity across 80 participants in the dose-escalation study.

investing.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-10-29
Description

ModeX Therapeutics entered into a license and collaboration agreement with Regeneron to develop multispecific antibodies using ModeX's MSTAR platform combined with Regeneron's proprietary binders. ModeX received $7 million upfront with potential milestone payments exceeding $200 million per selected molecule. The overall collaboration value could exceed $1 billion if multiple products advance successfully in immunology, oncology, and metabolic diseases. Regeneron funds preclinical, clinical, and commercial development.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

ModeX Therapeutics is an OPKO Health company. OPKO Health serves as the parent organization, providing corporate infrastructure, capital resources, and strategic oversight. OPKO Health reported Q4 2025 revenues of $148.5 million and has transformed its diagnostic business following the sale of BioReference's oncology division to Labcorp.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage oncology company developing bispecific antibodies (e.g., CTX1121) for hematologic and solid tumors. Comparable in modality and therapeutic area focus.

TypeDirect peer
Description

Develops multifunctional therapeutics platforms (Azymetric and EFFECT) for multispecific antibodies, with oncology pipeline assets in clinical development. Closely comparable technology positioning to ModeX's MSTAR platform.

TypeDirect peer
Description

Clinical-stage company developing T-cell engager (TCE) immunotherapies for solid tumors using a tumor-activated technology platform. Closely matches ModeX's MDX2003 tetraspecific T-cell engager approach.

TypeOthers
Description

Leading antibody discovery platform company providing engineering services and partnerships to biopharma. Comparable as an enabling platform player in the antibody engineering ecosystem that ModeX's MSTAR platform competes against for partner attention.

TypeEmerging player
Description

Antibody discovery company with proprietary platform technology for high-throughput antibody screening and partnership-based business model. Comparable platform-based, partner-driven approach.

TypeDirect peer
Description

Clinical-stage biotech developing bispecific antibodies (DART and TRIDENT platforms) primarily in oncology, including T-cell engagers. Comparable in modality (bispecific/multispecific antibodies) and therapeutic focus.

TypeDirect peer
Description

Pioneer in bispecific antibody engineering (Duobody platform) with multiple approved products (Darzalex, Rybrevant, Tecvayli) and a broad multispecific pipeline. Directly comparable to ModeX in modality focus on multispecific antibodies for oncology and immunology.

TypeEmerging player
Description

Clinical-stage immunology company developing infectious disease antibodies (including for SARS-CoV-2). Comparable in COVID-19 antibody program (Xevudy) and infectious disease antibody focus.

TypeDirect peer
Description

Develops T-cell engagers using a proprietary tri-specific T-cell engager (TriTAC) platform for solid tumors and hematologic malignancies. Comparable in oncology T-cell engager modality and clinical-stage profile.

TypeBroad incumbent
Description

Flagship ModeX collaboration partner and established leader in antibody therapeutics (Dupixent, Libtayo, REGN-COV). Comparable as a large incumbent in the multispecific antibody and antibody platform space.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ModeX Therapeutics

Biopharmaceutical Therapeuticsmodextx.com

ModeX Therapeutics is a clinical-stage biopharmaceutical subsidiary of OPKO Health that develops multispecific antibody therapeutics for oncology, infectious diseases, immunology, and metabolic disorders using proprietary MSTAR and Nanoparticle Vaccine platforms, monetized through licensing and milestone payments.

What ModeX Therapeutics does

ModeX Therapeutics is a clinical-stage biopharmaceutical company founded in 2020 and operating as a wholly-owned subsidiary of OPKO Health (NASDAQ: OPK). The company is headquartered at 20 Riverside Road, Weston, Massachusetts and employs 11–50 staff. Its scientific mission is to engineer multispecific antibodies — single molecules that engage multiple biological targets simultaneously — to address complex diseases in oncology, infectious disease, immunology, and metabolic disorders.

ModeX develops its candidates through two proprietary modular platforms: the MSTAR platform, which enables design of multispecific antibodies combining multiple biologics in a single molecule, and a Nanoparticle Vaccine Platform, which presents multiple antigens for infectious disease prevention. The current clinical pipeline comprises five programs: MDX2003 (tetraspecific T-cell engager in Phase I for relapsed/refractory B-cell lymphoma), MDX2301 (tetravalent bispecific COVID-19 antibody in Phase I, BARDA-funded), MDX2004 (trispecific antibody in Phase 1/2a for advanced cancers and immune disorders), an EBV vaccine in collaboration with Merck (Phase I, 200+ subjects enrolled), and a preclinical in-vivo CAR-T program targeting first-in-human trials by end-2026 or early-2027.

ModeX generates no product revenue; its economics flow from licensing and milestone payments under collaboration agreements and federal contract funding. The October 2025 Regeneron license and collaboration agreement delivered a $7M upfront with potential milestones exceeding $200M per selected molecule and an aggregate potential value above $1B. BARDA provides non-dilutive funding for the MDX2301 Phase 1 program. The Merck EBV vaccine partnership provides milestone-linked economics. Co-founders are Elias Zerhouni (Chairman; also OPKO Health President and Vice Chairman) and Gary Nabel (President and CEO; also OPKO Health Chief Innovation Officer). Scientific leadership includes CSO John Mascola (former Director of the NIH Vaccine Research Center, NIAID), COO Ji Zhang (formerly Senior Partner at Flagship Pioneering), and CMOs/CDOs with deep biotech drug-development backgrounds.

ModeX Therapeutics firmographics

Firmographics
Name
ModeX Therapeutics
Legal name
ModeX Therapeutics
Website
https://modextx.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
51–100 employees
Short description
ModeX Therapeutics is a clinical-stage biopharmaceutical subsidiary of OPKO Health that develops multispecific antibody therapeutics for oncology, infectious diseases, immunology, and metabolic disorders using proprietary MSTAR and Nanoparticle Vaccine platforms, monetized through licensing and milestone payments.
Ownership category
akta.pro rank

ModeX Therapeutics industry classification

Industry
Product category
Biopharmaceutical Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)

Keywords

  • Multispecific antibody therapeutics
  • Bispecific antibody engineering
  • Immuno-oncology biologics
  • Infectious disease antibodies
  • Nanoparticle vaccine development

Where ModeX Therapeutics is headquartered

Location

Headquarters

HQ city
Weston
HQ country
United States
HQ region
North America

Offices1 record

Markets served

ModeX Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Licensing and Milestone Payments (Regeneron Collaboration): ModeX receives upfront payments and potential milestone payments exceeding $200 million per selected molecule from Regeneron, with overall collaboration value exceeding $1 billion if multiple products advance successfully. Revenue is generated through preclinical, clinical, and commercial milestones.
  2. Federal Contract Funding (BARDA): ModeX receives federal funding from the U.S. Biomedical Advanced Research and Development Authority (BARDA) for the MDX2301 COVID-19 antibody program, supporting Phase 1 clinical trial costs.
  3. Collaboration Revenue (Merck EBV Vaccine): OPKO's collaboration with Merck involves an Epstein-Barr virus vaccine study that has enrolled over 200 subjects in Phase 1, with milestone payments tied to subgroup analyses and Phase II design decisions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

ModeX Therapeutics product offering

Product offering

Core offering

ModeX Therapeutics is a clinical-stage biopharmaceutical company developing multispecific antibody therapeutics using its proprietary MSTAR Platform and Nanoparticle Vaccine Platform. The company engineers single molecules that combine multiple biologics to simultaneously target distinct biological pathways, addressing cancer, infectious diseases, immunology, and metabolic disorders. Its pipeline includes MDX2003 (tetraspecific T-cell engager for B-cell lymphoma), MDX2301 (tetravalent bispecific antibody for COVID-19 prevention), MDX2004 (trispecific antibody for advanced cancers and immune disorders), an EBV vaccine developed with Merck, and an in-vivo CAR-T program.

Product overview

ModeX Therapeutics is a biopharmaceutical company developing multispecific antibody therapeutics using its proprietary modular platforms. The company operates two core technology platforms: the MSTAR Platform for developing multispecific antibodies and a Nanoparticle Vaccine Platform. The clinical pipeline includes MDX2003 (tetraspecific T-cell engager for B-cell lymphoma), MDX2301 (tetravalent bispecific antibody for COVID-19 prevention), MDX2004 (trispecific antibody for advanced cancers and immune disorders), an EBV vaccine (in collaboration with Merck), and an in-vivo CAR-T program. ModeX is a subsidiary of OPKO Health and has a strategic collaboration with Regeneron worth over $1 billion to develop multispecific antibodies targeting immunology, oncology, and metabolic diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • MDX2003
  • MDX2301
  • MDX2004
  • Epstein-Barr Virus (EBV) Vaccine

Quantifiable outcome

  • Over five tetraspecific antibodies are currently in clinical trials with first approval expected by 2032
  • +2 more outcomes

Companies that use ModeX Therapeutics

Customer profile

Segments4 records

Ideal customer profiles3 records

ModeX Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

ModeX Therapeutics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and flagship.

  • MerckcoreStrategic or Co-development Partner · 28 April 2026OPKO Health's collaboration with Merck involves an Epstein-Barr virus (EBV) vaccine study that has enrolled over 200 subjects in a Phase 1 study, with subgroup analyses underway. Data is expected to inform Phase II design by year-end.
  • U.S. Biomedical Advanced Research and Development Authority (BARDA)coreStrategic or Co-development Partner · 9 April 2026BARDA is funding the Phase 1 clinical trial of MDX2301, a tetravalent bispecific antibody for COVID-19 prevention, under a federal contract from the U.S. Department of Health and Human Services. The funding supports evaluation of safety, tolerability, pharmacokinetics, and neutralizing activity across 80 participants in the dose-escalation study.
  • Regeneron PharmaceuticalsflagshipStrategic or Co-development Partner · 29 October 2025ModeX Therapeutics entered into a license and collaboration agreement with Regeneron to develop multispecific antibodies using ModeX's MSTAR platform combined with Regeneron's proprietary binders. ModeX received $7 million upfront with potential milestone payments exceeding $200 million per selected molecule. The overall collaboration value could exceed $1 billion if multiple products advance successfully in immunology, oncology, and metabolic diseases. Regeneron funds preclinical, clinical, and commercial development.
  • OPKO HealthflagshipStrategic or Co-development PartnerModeX Therapeutics is an OPKO Health company. OPKO Health serves as the parent organization, providing corporate infrastructure, capital resources, and strategic oversight. OPKO Health reported Q4 2025 revenues of $148.5 million and has transformed its diagnostic business following the sale of BioReference's oncology division to Labcorp.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

ModeX Therapeutics competitors and assessment

Company assessment

Direct peers

  • Compass Therapeutics: Clinical-stage oncology company developing bispecific antibodies (e.g., CTX1121) for hematologic and solid tumors. Comparable in modality and therapeutic area focus.
  • Zymeworks: Develops multifunctional therapeutics platforms (Azymetric and EFFECT) for multispecific antibodies, with oncology pipeline assets in clinical development. Closely comparable technology positioning to ModeX's MSTAR platform.
  • Janux Therapeutics: Clinical-stage company developing T-cell engager (TCE) immunotherapies for solid tumors using a tumor-activated technology platform. Closely matches ModeX's MDX2003 tetraspecific T-cell engager approach.
  • MacroGenics: Clinical-stage biotech developing bispecific antibodies (DART and TRIDENT platforms) primarily in oncology, including T-cell engagers. Comparable in modality (bispecific/multispecific antibodies) and therapeutic focus.
  • Genmab: Pioneer in bispecific antibody engineering (Duobody platform) with multiple approved products (Darzalex, Rybrevant, Tecvayli) and a broad multispecific pipeline. Directly comparable to ModeX in modality focus on multispecific antibodies for oncology and immunology.
  • Harpoon Therapeutics: Develops T-cell engagers using a proprietary tri-specific T-cell engager (TriTAC) platform for solid tumors and hematologic malignancies. Comparable in oncology T-cell engager modality and clinical-stage profile.

Others

  • Adimab: Leading antibody discovery platform company providing engineering services and partnerships to biopharma. Comparable as an enabling platform player in the antibody engineering ecosystem that ModeX's MSTAR platform competes against for partner attention.

Emerging players

  • AbCellera Biologics: Antibody discovery company with proprietary platform technology for high-throughput antibody screening and partnership-based business model. Comparable platform-based, partner-driven approach.
  • Vir Biotechnology: Clinical-stage immunology company developing infectious disease antibodies (including for SARS-CoV-2). Comparable in COVID-19 antibody program (Xevudy) and infectious disease antibody focus.

Broad incumbents

  • Regeneron Pharmaceuticals: Flagship ModeX collaboration partner and established leader in antibody therapeutics (Dupixent, Libtayo, REGN-COV). Comparable as a large incumbent in the multispecific antibody and antibody platform space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

ModeX Therapeutics social profiles

Digital presence

ModeX Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ModeX Therapeutics leadership team

Management profile

Number of profiles

Profiles6 records

ModeX Therapeutics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ModeX Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ModeX Therapeutics

What does ModeX Therapeutics do?

ModeX Therapeutics is a clinical-stage biopharmaceutical company developing multispecific antibody therapeutics using its proprietary MSTAR Platform and Nanoparticle Vaccine Platform. The company engineers single molecules that combine multiple biologics to simultaneously target distinct biological pathways, addressing cancer, infectious diseases, immunology, and metabolic disorders. Its pipeline includes MDX2003 (tetraspecific T-cell engager for B-cell lymphoma), MDX2301 (tetravalent bispecific antibody for COVID-19 prevention), MDX2004 (trispecific antibody for advanced cancers and immune disorders), an EBV vaccine developed with Merck, and an in-vivo CAR-T program.

Is ModeX Therapeutics a public or private company?

ModeX Therapeutics is a private company. It is classified as corporate owned and is currently operating.

When was ModeX Therapeutics founded?

ModeX Therapeutics was founded in 2020. It employs 51 to 100 people.

Where is ModeX Therapeutics based?

ModeX Therapeutics is headquartered in Weston, United States, in the North America region.

How does ModeX Therapeutics make money?

Three revenue lines are on record. Licensing and Milestone Payments (Regeneron Collaboration) is the primary driver. The others are federal Contract Funding (BARDA) and collaboration Revenue (Merck EBV Vaccine).

Who are ModeX Therapeutics's main competitors?

Direct peers on record are Compass Therapeutics, Zymeworks, Janux Therapeutics, MacroGenics, Genmab and Harpoon Therapeutics. Adimab is listed as an others. Emerging players are AbCellera Biologics and Vir Biotechnology. Regeneron Pharmaceuticals is listed as a broad incumbent.

Does ModeX Therapeutics have an API?

No public API is recorded for ModeX Therapeutics.

What industry is ModeX Therapeutics in?

ModeX Therapeutics's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireTetraspecific Antibodies Clinical Pipeline Market research 2026: Development Technologies, Therapeutic Approaches & Market Opportunity Insight to 2032ResearchAndMarkets.com has published a market research report on tetraspecific antibodies covering clinical trials, development technologies, and market opportunity from 2026 through 2032. The report indicates that over five tetraspecific antibodies are currently in clinical trials, with the first approval expected by 2032, and profiles key players including ModeX Therapeutics conducting Phase I studies for MDX2003 in B-cell lymphomas and Shanghai Henlius Biotech approved for trials of HLX3901 in advanced solid tumors. The analysis highlights the growing pipeline driven by demand for more efficacious cancer therapeutics that can address antigen escape and drug resistance limitations of earlier antibody generations.Clinical Trials ArenaModeX starts dosing in MDX2003 trial for B-cell lymphomaModeX Therapeutics began dosing patients with its tetraspecific T-cell engager MDX2003 for relapsed or refractory B-cell lymphoma. The MDX-2003-101 study assesses tolerability, pharmacokinetics, safety, and immune activity, including dose-escalation and expansion segments. Preclinical data was presented at ASH 2025 and ESMO 2026.GlobeNewswireOPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell LymphomasModeX Therapeutics began dosing patients with MDX2003, a tetraspecific T-cell engager targeting CD19, CD20, CD3, and CD28, in a Phase 1 study for relapsed or refractory B-cell lymphoma. The study includes dose-escalation and expansion phases, with preclinical data presented at ASH 2025 and ESMO 2026.BioSpaceOPKO Health’s ModeX Therapeutics Begins Clinical Trial of Tetraspecific Antibody for Treatment of B-cell LymphomasModeX Therapeutics began dosing patients with its first-in-class tetraspecific T-cell engager MDX2003 for relapsed or refractory B-cell lymphoma. The Phase 1 study (NCT07249905) evaluates safety, tolerability, pharmacokinetics, and immune activity, targeting CD19, CD20, CD3, and CD28. Preclinical data was presented at ASH 2025 and ESMO 2026.GlobeNewswireOPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19ModeX Therapeutics initiated a Phase 1 clinical trial of MDX2301, a tetravalent bispecific antibody, for COVID-19 prevention. The trial evaluates safety and tolerability in healthy volunteers and high-risk adults, with 80 participants expected. The study is funded by U.S. federal funds.BioSpaceOPKO Health’s ModeX Therapeutics Initiates Clinical Trial of MDX2301 for the Prevention of COVID-19ModeX Therapeutics, an OPKO Health company, announced that the first participants have been dosed in a Phase 1 clinical trial evaluating MDX2301, a tetravalent bispecific antibody designed to neutralize all known SARS-CoV-2 variants for COVID-19 prevention. The randomized, double-blind, placebo-controlled study will enroll 80 participants and evaluate safety, tolerability, pharmacokinetics, and neutralizing activity across intravenous, intramuscular, and subcutaneous administration routes. The trial is being funded by the U.S. Biomedical Advanced Research and Development Authority under a federal contract, and the company notes the platform could potentially address other viral threats such as influenza.The Independent Florida AlligatorUF researchers pessimistic after federal vaccine funding cutsThe U.S. Department of Health and Human Services terminated $500 million in mRNA vaccine research funding, including 22 development contracts with entities such as Pfizer, Moderna, and ModeX, effective August 5, 2025. This decision, attributed to HHS Secretary Robert F. Kennedy Jr., has halted new programs and caused significant concern among university researchers at institutions like the University of Florida and Johns Hopkins regarding future scientific capabilities.GlobeNewswireOPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic IndicationsModeX Therapeutics entered a license and collaboration agreement with Regeneron to develop multispecific antibodies for several therapeutic indications. ModeX will receive an upfront payment of $7 million, with potential future payments exceeding $200 million per selected molecule, and the overall value potentially exceeds $1 billion if multiple products succeed.GlobeNewswireOPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic IndicationsModeX Therapeutics entered a license and collaboration agreement with Regeneron to develop multispecific antibodies for several therapeutic indications. ModeX will receive an upfront payment of $7 million and potential future payments exceeding $200 million per selected molecule, with total value potentially exceeding $1 billion.YahooOPKO Health’s ModeX Therapeutics Enters into Research Collaboration with Regeneron to Develop Multispecific Antibodies for Select Therapeutic IndicationsModeX Therapeutics, an OPKO Health company, entered a license and collaboration agreement with Regeneron to develop multispecific antibodies. ModeX will receive an upfront payment of $7 million and potential milestone payments exceeding $200 million per selected molecule, with total value potentially exceeding $1 billion. Regeneron will fund and lead development and commercialization.